<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EF73B9AD-68DD-4A27-81E2-446F98113484"><gtr:id>EF73B9AD-68DD-4A27-81E2-446F98113484</gtr:id><gtr:name>Orphan Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D596C892-7087-4F4E-A2A2-E5937A2615E0"><gtr:id>D596C892-7087-4F4E-A2A2-E5937A2615E0</gtr:id><gtr:name>St. George's Hospital Medical School</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/76BB6D9B-FD59-4BE0-A34F-A11BA8058B99"><gtr:id>76BB6D9B-FD59-4BE0-A34F-A11BA8058B99</gtr:id><gtr:name>University Hospital Spedali Civili</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5C1114A7-CE62-4DEC-BB95-695D6E2666CF"><gtr:id>5C1114A7-CE62-4DEC-BB95-695D6E2666CF</gtr:id><gtr:name>University of Verona</gtr:name><gtr:address><gtr:line1>strada le Grazie 15</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/00866200-F62B-429B-BF02-A0A841684ED5"><gtr:id>00866200-F62B-429B-BF02-A0A841684ED5</gtr:id><gtr:name>University of Salamanca</gtr:name><gtr:address><gtr:line1>Universidad de Salamanca</gtr:line1><gtr:line2>Patio de Escuelas 1</gtr:line2><gtr:line4>Salamanca</gtr:line4><gtr:line5>37071</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:department>Clinical Developmental Sciences</gtr:department><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EF73B9AD-68DD-4A27-81E2-446F98113484"><gtr:id>EF73B9AD-68DD-4A27-81E2-446F98113484</gtr:id><gtr:name>Orphan Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D596C892-7087-4F4E-A2A2-E5937A2615E0"><gtr:id>D596C892-7087-4F4E-A2A2-E5937A2615E0</gtr:id><gtr:name>St. George's Hospital Medical School</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/76BB6D9B-FD59-4BE0-A34F-A11BA8058B99"><gtr:id>76BB6D9B-FD59-4BE0-A34F-A11BA8058B99</gtr:id><gtr:name>University Hospital Spedali Civili</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5C1114A7-CE62-4DEC-BB95-695D6E2666CF"><gtr:id>5C1114A7-CE62-4DEC-BB95-695D6E2666CF</gtr:id><gtr:name>University of Verona</gtr:name><gtr:address><gtr:line1>strada le Grazie 15</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/00866200-F62B-429B-BF02-A0A841684ED5"><gtr:id>00866200-F62B-429B-BF02-A0A841684ED5</gtr:id><gtr:name>University of Salamanca</gtr:name><gtr:address><gtr:line1>Universidad de Salamanca</gtr:line1><gtr:line2>Patio de Escuelas 1</gtr:line2><gtr:line4>Salamanca</gtr:line4><gtr:line5>37071</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E7256C93-C8B3-4E2C-91FF-1BAF197AB107"><gtr:id>E7256C93-C8B3-4E2C-91FF-1BAF197AB107</gtr:id><gtr:firstName>Bridget</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Bax</gtr:surname><gtr:orcidId>0000-0001-6306-080X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0CEDEF28-C1FC-4179-9AEE-F29B4AE777DC"><gtr:id>0CEDEF28-C1FC-4179-9AEE-F29B4AE777DC</gtr:id><gtr:firstName>Murray D</gtr:firstName><gtr:surname>Bain</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6025B9C5-FE7E-461E-B8AD-9111206CBFA2"><gtr:id>6025B9C5-FE7E-461E-B8AD-9111206CBFA2</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>Frederick</gtr:otherNames><gtr:surname>Moran</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0902179"><gtr:id>2F7DF620-3384-4CF8-A987-FAC096A5BF72</gtr:id><gtr:title>Pre-clinical safety studies of erythrocyte encapsulated thymidine phosphorylase</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0902179</gtr:grantReference><gtr:abstractText>MNGIE (Mitochondrial neurogastrointestinal encephalomyopathy) is a life-threatening inherited metabolic disorder caused by a defect in the gene coding for the enzyme thymidine phosphorylase, resulting in affected individuals producing little or no active enzyme. Thymidine phosphorylase is essential for the normal metabolism of DNA metabolites, and in its absence, these metabolites accumulate in the body producing toxic effects on the nervous system and skeletal muscle, causing gastrointestinal dysmotility (e.g. vomiting and anorexia), neuropathy (nerve damage leading to, for example, loss of sensation and abnormal eye movements) and severe muscle weakness. MNGIE is relentlessly progressive with patients dying at an average reported age of 38 years. No specific treatment is currently available. The research team at St. George?s University of London are world leaders in developing the red blood cell as a vehicle for carrying therapeutic proteins in the blood. In the current study they are investigating the effectiveness of using patient?s own red blood cells to carry the missing thymidine phosphorylase in the circulation. The red blood cells provide a protected environment in which the enzyme can function. The encapsulated enzyme reduces the levels of toxic metabolites in the blood, thus relieving the nervous system and muscle of their toxic effects. The aim of this proposal is to conduct pre-clinical safety studies in two animal species and to establish a manufacturing process for the production of clinical grade thymidine phosphorylase; the data obtained will support their application to the UK and USA regulatory bodies to extend this work into a phase II/III clinical trials programme. Results from these studies will be made available to patient support groups and charities specialising in rare inherited metabolic disorders.</gtr:abstractText><gtr:technicalSummary>Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a fatal inherited metabolic disorder caused by a deficiency of thymidine phosphorylase, leading to a pathological accumulation of thymidine and deoxyuridine. MNGIE is relentlessly progressive with patients dying at an average age of 37.6 years. There is no recognised treatment. The encapsulation of therapeutic enzymes within autologous erythrocytes is an approach for enzyme replacement therapy which is employed clinically by our group. Encapsulation within the erythrocyte has the advantage of maintaining enzyme activity within the circulation for the life span of the erythrocyte and preventing the formation of inactivating antibodies against the enzyme. This approach is applicable to disorders where pathologically elevated plasma metabolites are able to permeate the erythrocyte membrane. Preliminary data from our clinical pilot studies of erythrocyte encapsulated thymidine phosphorylase show a reduction in plasma thymidine. The aim of this proposal is to obtain regulatory pre-clinical toxicity data from two animal species, and to establish a GMP-compliant manufacturing pathway for recombinant thymidine phosphorylase for clinical use. Both will make a significant contribution to our clinical trial applications to the regulatory bodies, the MHRA and the FDA, from which approval will be sought to develop this investigational therapy into a clinical trials programme.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>559673</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Verona</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Neurological Sciences and Vision</gtr:department><gtr:description>MNGIE: An Italian network for MNGIE epidemiology, molecular mechanismsand enzyme replacement therapy by stem cell transplant</gtr:description><gtr:id>BDF9E847-E6AF-439F-9670-EEF879CB0120</gtr:id><gtr:impact>A network of Italian clinicians (neurologists, gastroenterologists) and European researchers has been established, who have experience in MNGIE. The aim is to share information in order to better understand the frequency, natural history and clinical aspects of this complex and rare disease, and to share protocols for both pre-treatment and follow-up studies.</gtr:impact><gtr:partnerContribution>The research team has diagnosed two patients with MNGIE via this collaboration, providing the research team with two potential patients for the Clinical trial they are intending to initiate. Plasma and urine samples have been donated to the research team's Biomarker study.Supply of plasma and urine samples for Research team's Biomarker study</gtr:partnerContribution><gtr:piContribution>Sharing data obtained from the treatment of patients with enzyme replacement therapy with thymidine phosphorylase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Spedali Civili</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Clinical Neurology</gtr:department><gtr:description>MNGIE: An Italian network for MNGIE epidemiology, molecular mechanismsand enzyme replacement therapy by stem cell transplant</gtr:description><gtr:id>06421D15-34CC-460B-8376-06E8FE24A089</gtr:id><gtr:impact>A network of Italian clinicians (neurologists, gastroenterologists) and European researchers has been established, who have experience in MNGIE. The aim is to share information in order to better understand the frequency, natural history and clinical aspects of this complex and rare disease, and to share protocols for both pre-treatment and follow-up studies.</gtr:impact><gtr:partnerContribution>The research team has diagnosed two patients with MNGIE via this collaboration, providing the research team with two potential patients for the Clinical trial they are intending to initiate. Plasma and urine samples have been donated to the research team's Biomarker study.Supply of plasma and urine samples for Research team's Biomarker study</gtr:partnerContribution><gtr:piContribution>Sharing data obtained from the treatment of patients with enzyme replacement therapy with thymidine phosphorylase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Orphan Technologies</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Commercial partnership</gtr:description><gtr:id>4AC0EDE4-0CA5-4922-8351-3F8BED8DEFAC</gtr:id><gtr:impact>Recent submission of DPFS/DCS MRC application</gtr:impact><gtr:partnerContribution>Expertise in regulatory issues, manufacturing to GMP, clinical trial activities</gtr:partnerContribution><gtr:piContribution>Intellectual knowledge, expertise in EE-TP manufacture, knowledge of disease (MNGIE)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Salamanca</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Collaboration with University of Salamanca</gtr:description><gtr:id>BAE798DF-CD37-4E02-BE03-9E1A007CCCDC</gtr:id><gtr:impact>Award of two PhDs by the University of Salamanca.

For one student, the Principal Investigator was the First Vocal at the PhD Tribunal.

One publication: Pub med reference number18674740</gtr:impact><gtr:partnerContribution>Two PhD students worked in Principal Investigator's laboratory for six months each to exchange animal/human experience with red cells as drug carriers.</gtr:partnerContribution><gtr:piContribution>Provided training and experience with handling human erythrocytes and training using the Prinicipal Investigator's loading technique</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lisbon</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>Bioinformatics collaboration</gtr:description><gtr:id>8F47BC81-23F3-41CA-8DF1-606E29FE6094</gtr:id><gtr:impact>miRNA- gene target networks
Enrichment analysis of miRNA targets
PhD thesis</gtr:impact><gtr:partnerContribution>Training in the use of bioinformatic databases, and pathway analysis</gtr:partnerContribution><gtr:piContribution>Sharing data for bioinformatic analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. George's Hospital Medical School</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Basic Medical Sciences</gtr:department><gtr:description>Characterisation of biomarkers for monitoring disease progression and treatment efficacy in MNGIE</gtr:description><gtr:id>54B07F94-2929-4280-B339-1B49C3C2C141</gtr:id><gtr:impact>Funding for a PhD studentship</gtr:impact><gtr:partnerContribution>Provided guidance on the appropriate techniques to be employed in project</gtr:partnerContribution><gtr:piContribution>Analysed preliminary data and wrote/submitted grant application,</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1EE78020-60B2-4B9D-9680-CAEFB1D814A4</gtr:id><gtr:impact>Global dissemination resource for the wider scientific, technology and research communities

Contacted by patients with MNGIE for update on availability of therapy in the USA and Turkey</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.research-europe.com</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rare Disease Day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>463E32D6-A144-4268-A198-72624347F444</gtr:id><gtr:impact>International MNGIE Consortium Meeting and Innsbruck Rare Disease Day Symposium 2016

Monday, February 29 2016, Innsbruck
Presentation of recent / interesting issues: 
Discussions on Liver cirrhosis in MNGIE, liver transplantation and gene therapy using an AAV vector</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient/clinician seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>10693599-2B78-4C8D-BFF3-CDABF944D9A3</gtr:id><gtr:impact>40 individuals (health professionals, researchers, patient carers and diagnostic laboratory staff) attended a seminar on raising the awareness of MNGIE.

Summary of seminar sent out to patients and carers via Newsletter. 

Participating clinician of the Association of British Neurologist entered details of clinical study to monthly electronic newsletter sent out by British Neurological Surveillance Unit.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>14280</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Higher Education Funding Council for Britain</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>St George's University of London</gtr:fundingOrg><gtr:id>94D966C5-E6DB-4FB2-B035-AD2BAFB26BB4</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>957271</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>South Central Specialised Commissioning Group</gtr:department><gtr:description>Specialised Patient care</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>Northamptonshire Healthcare NHS Foundation Trust</gtr:fundingOrg><gtr:id>C91C9A0D-E091-4694-A2FE-171B75553AC0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98922</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>. The development of knock-out cell culture models for investigating the underlying molecular mechanisms that contribute to the neuronal aspects of Mitochondrial Neurogastrointestinal Encephalomyopathy</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Purine Metabolic Patients? Association (PUMPA)</gtr:fundingOrg><gtr:id>2D0061E9-F395-465B-A105-58D70C868C6C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Specialised Equipment</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Purine Metabolic Patients? Association (PUMPA)</gtr:fundingOrg><gtr:id>8909438A-240B-4D58-8996-494FDCE7DB47</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>76680</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Principal Investigator award</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>United Mitochondrial Disease Foundation</gtr:fundingOrg><gtr:id>4942A115-153C-479A-93C8-7269AB142C18</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Purine Metabolic Patients? Association (PUMPA)</gtr:fundingOrg><gtr:id>2FC7A1D6-8C18-4C0A-B126-9EC6F10EB0D6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Enzyme replacement therapy for a rare inherited metabolic disease. Enzyme is encapsulated in patients red blood cells.</gtr:description><gtr:id>F6430FB3-8F1A-4F79-8570-ECCD46C40357</gtr:id><gtr:impact>Increased awareness in patient and clinician community. Requests for compassionate use. International Health authorities funding compassionate therapy.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>GB1116767.3</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>EE-TP therapy for MNGIE disease</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The product under development is erythrocyte encapsulated thymidine phosphorylase (EE-TP) for the treatment of MNGIE. The thymidine phosphorylase developed is a recombinant enzyme and to date thre engineering batches have been produced for clinical trial use. Master and working cell banks have been created.</gtr:description><gtr:id>53364136-FE7B-4D28-8C70-24E59700D60F</gtr:id><gtr:impact>The product has been employed in the compassionate use setting and has eliminated previously observed immune reactions that were observed using a less purified version</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>GMP Working Cell bank for thymidine phosphorylase</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The product under development is erythrocyte encapsulated thymidine phosphorylase (EE-TP) for the treatment of MNGIE. The thymidine phosphorylase developed is a recombinant enzyme and to date thre engineering batches have been produced for clinical trial use. Master and working cell banks have been created. The development is funded by the MRC.</gtr:description><gtr:id>0A55C946-E3DE-47B2-BA43-0098E5D2AB43</gtr:id><gtr:impact>Documentation from manufacture will support clinical trial application</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>GMP thymidine phosphorylase</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The production of a pre GMP recombinant E. coli thymidine phosphorylase. The production has been adapted to processes which are compatible for GMP production. Modifications in the production process were made to minimise hazardous materials, exclude the use of animal-derived products and reduce endotoxin levels.</gtr:description><gtr:id>C09B58E1-9249-4503-931B-40A7A9BE21C0</gtr:id><gtr:impact>The development of a refined preparation of thymidine phosphorylase has provided the investigators with an clinical grade enzyme; this has resulted in an amelioration of the mild adverse reactions previously observed on infusion in the investigators compassionate use of this therapy.

The availibility of Master Manufacturing Formula documentation to support a clinical trial application to the MHRA.</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Thymidine phosphorylase</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Production of three batches of GMP thymidine phosphorylase for a clinical trial of EE-TP for the treatment of MNGIE</gtr:description><gtr:id>A9FEF895-EF10-45A5-868C-AC4955A978DB</gtr:id><gtr:impact>Three validation batches have provided data to support IMPD and pre-submission briefing package to EMA</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GMP -TP</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>GLP-compliant toxicity data from two animal species to support a clinical trial application to the regulatory bodies</gtr:description><gtr:id>660C8AAA-DC87-4D63-B45D-E9635455E2E9</gtr:id><gtr:impact>Orphan Drug designation approval by FDA and EMA for therapetic approach

Production of a Clinical Trial Application package

Expression of collaboration interest from four biotechnology Companies</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GLP toxicity data</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Validated GLP-compliant immunoassay for the detection of anti-thymidine phosphorylase antibodies for use in a clinical trial</gtr:description><gtr:id>4C0E2CC9-EAF8-45B2-8A6A-87DE35092C05</gtr:id><gtr:impact>Reliable and accurate assay for monitoring antibodies in the clinical application of thymidine phosphorylase. 

Orphan Drug designation granted by FDA and EMA for therapeutic approach

Data supports Clinical trial application to MHRA</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GLP immunoassay</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Validated immunoassay for the measurement of human anti-thymidine phosphorylase antibodies in patients treated with EE-TP</gtr:description><gtr:id>D6647EE6-3412-4E29-8B81-839B6DFC9AEF</gtr:id><gtr:impact>Suppporting documentation for clinical trial of EE-TP</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GLP immunoassay for EE-TP clinical trial</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Assay validated for the measurement of EE-TP to support QP release in Clinical trial</gtr:description><gtr:id>98941175-C859-4AC7-B052-A4178AE6CCC1</gtr:id><gtr:impact>Quantification of doses given to patients in compassionate use</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Validated HPLC assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15F4D683-73B5-4622-9D38-425CE9B924F9"><gtr:id>15F4D683-73B5-4622-9D38-425CE9B924F9</gtr:id><gtr:title>Poor Outcome in a Mitochondrial Neurogastrointestinal Encephalomyopathy Patient with a Novel TYMP Mutation: The Need for Early Diagnosis.</gtr:title><gtr:parentPublicationTitle>Case reports in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8a459cbd441b7638df988d50cd2625e"><gtr:id>c8a459cbd441b7638df988d50cd2625e</gtr:id><gtr:otherNames>Scarpelli M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1662-680X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/51F92916-E9FB-4BA6-AAA2-06BA29B2DEB1"><gtr:id>51F92916-E9FB-4BA6-AAA2-06BA29B2DEB1</gtr:id><gtr:title>Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9fe6299f500d25ab5be75dc6010c9e82"><gtr:id>9fe6299f500d25ab5be75dc6010c9e82</gtr:id><gtr:otherNames>Bax BE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BC21BE31-718D-440C-A020-7DF5CEC5EB59"><gtr:id>BC21BE31-718D-440C-A020-7DF5CEC5EB59</gtr:id><gtr:title>Differences in collagen ultrastructure of human first trimester decidua basalis and parietalis: implications for trophoblastic invasion of the placental bed.</gtr:title><gtr:parentPublicationTitle>The journal of obstetrics and gynaecology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a6dd3ba59860ca00a0fff35c4ddee941"><gtr:id>a6dd3ba59860ca00a0fff35c4ddee941</gtr:id><gtr:otherNames>Sinai Talaulikar V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1341-8076</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B28A4FDA-FA45-488B-ADF3-5A17DFE8E247"><gtr:id>B28A4FDA-FA45-488B-ADF3-5A17DFE8E247</gtr:id><gtr:title>Mitochondrial neurogastrointestinal encephalopathy without elevated thymidine levels.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/169de2519106739054db3af2036d45e3"><gtr:id>169de2519106739054db3af2036d45e3</gtr:id><gtr:otherNames>Moran NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12FBB07F-34B7-4374-8FA0-EF42B15135F3"><gtr:id>12FBB07F-34B7-4374-8FA0-EF42B15135F3</gtr:id><gtr:title>The development and validation of an immunoassay for the measurement of anti-thymidine phosphorylase antibodies in mouse and dog sera.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical and biomedical analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ed752ec848d4caf20a8d3840662cb2e"><gtr:id>9ed752ec848d4caf20a8d3840662cb2e</gtr:id><gtr:otherNames>Gasson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0731-7085</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A0288BE-1DA3-44B1-A447-5F5D22281A74"><gtr:id>9A0288BE-1DA3-44B1-A447-5F5D22281A74</gtr:id><gtr:title>Validation of a HPLC method for the measurement of erythrocyte encapsulated thymidine phosphorylase (EE-TP) activity.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical and biomedical analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b9c5353901f6f0f0a28dae91b2d1e61"><gtr:id>1b9c5353901f6f0f0a28dae91b2d1e61</gtr:id><gtr:otherNames>Fairbanks LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0731-7085</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1EBB1806-40DD-404A-A80A-25968948B2ED"><gtr:id>1EBB1806-40DD-404A-A80A-25968948B2ED</gtr:id><gtr:title>International seminar on the red blood cells as vehicles for drugs.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89b6a9cfc1fef94032db94f310da1312"><gtr:id>89b6a9cfc1fef94032db94f310da1312</gtr:id><gtr:otherNames>Godfrin Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22757845-1D9B-4C5D-AB48-44136A1F81A3"><gtr:id>22757845-1D9B-4C5D-AB48-44136A1F81A3</gtr:id><gtr:title>Preclinical toxicity evaluation of erythrocyte-encapsulated thymidine phosphorylase in BALB/c mice and beagle dogs: an enzyme-replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b2c2249d8481dd0b5dac83f6eb38c55"><gtr:id>4b2c2249d8481dd0b5dac83f6eb38c55</gtr:id><gtr:otherNames>Levene M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902179</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>